PCI to Expand Bridgend Facility

Published on: 

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-10-05-2016, Volume 11, Issue 10

The company will add a new clinical services facility at Central Park on Bridgend Industrial Estate.

PCI announced it will be expanding its Bridgend, South Wales, United Kingdom clinical site. Ground works and construction began on Sept. 12, 2016 of a new clinical services facility at Central Park on Bridgend Industrial Estate, one of four PCI European-based locations supporting investigational study materials.

The facility expansion at the Bridgend location will provide 37,500 square feet of additional space in support of the secondary packaging and logistical services provided at the Clinical Services Center of Excellence. PCI facilities have the capacity to handle cold chain and ultra-cold chain pharmaceuticals at temperatures ranging from controlled ambient 15–25 °C, 2–8 °C, down to -20 °C, -30 °C -40 °C, -60 °C to -90 °C. The facilities also offer liquid nitrogen vapor phase storage below -150 °C for advanced therapeutic medicinal products (ATMPs), as well as bespoke refrigerated and frozen temperatures.

This is the latest in a series of investments by PCI in developing its Bridgend site, most recently with a -40 °C facility; as well as a broader cold-chain capacity expansion that increased site storage by more than 400%; in addition to continued expansion of frozen storage at -80 °C. These investments at Bridgend mirror PCI investments at other European and North American sites, supporting services for clinical trials and its considerable business growth in this segment. The new building, which is expected to open for business in early 2018, will be adjacent to PCI’s current facilities at Bridgend. The facility will also include additional office space to meet staff growth plans.


Source: PCI